Contact

• ISPOR 2020 Publications in Value in Health​​

  • Cost-Utility model of Trastuzumab Emtansine (T-DM1) in HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer Previously Treated with Trastuzumab and a Taxane, Compared with Capecitabine PLUS Lapatinib, Trastuzumab PLUS Capecitabine and Capecitabine alone in Turkey

  •  Cost-Effectiveness (CE) Analysis of Trastuzumab Emtansine for Adjuvant Treatment of Adult Patients with HER2+ EARLY Breast Cancer in Turkey

​

• ISPOR 2019​ Publications in Value Health:

  • 1. CE analysis of pirfenidone tablets compared with best supportive care for idiopathic pulmonary fibrosis (ipf) treatment in Turkey
    2. CE analysis of pirfenidone tablets compared with nintedanib for idiopathic pulmonary fibrosis (ipf) treatment in Turkey
    3. Health economics model of precision medicine genomic profiling Foundation
    One cdx®  in locally advanced or metastatic non-small cell lung cancer 
    4. CE of obinutuzumab plus bendamustine vs bendamustine alone for patients who did not respond or progressed during or after rituximab or a rituximab containing regiment in Turkey

  •  5 i) CE analysis of tocilizumab sc in comparison with anakinra in systemic idiopathic juvenile arthritis (sjia) treatment in Turkey 
    ii) CE analysis of tocilizumab sc in polyarticular juvenile idiopathic arthritis (pjia) treatment in Turkey 

  • 7. CE of pertuzumab plus trastuzumab vs trastuzumab in neoadjuvant setting based on the Neosphere trial in Turkey

​

• Book chapters: Global impact of reference pricing,  by Rabia Kahveci (Referans Fiyatlandırmanın Global Etkisi). Rabia Kahveci baş editörlüğünde kitap basımı, İlaç ve pazara erişim süreci; Fiyatlandırma ve Geri Ödeme Politikaları, 2017, Sage Yayıncılık

​

• For previous works and publications of Esen Erdoğan-Çiftçi please contact us.